Data completeness
1/8 — Limited
VAPO-ISO (isoproterenol hydrochloride) by Medica Corp is beta-adrenergic agonist with very low affinity for alpha-adrenergic receptors.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VAPO-ISO is an inhaled solution of isoproterenol hydrochloride, a beta-adrenergic agonist with minimal alpha-adrenergic activity. It is indicated for bronchospasm relief and airway obstruction management via inhalation. The drug works by stimulating beta-adrenergic receptors to promote bronchodilation and improve respiratory airflow.
Pre-Launch
Pre-launch stage indicates early-phase commercial infrastructure building with potential for rapid team expansion upon market entry.
Mechanism of Action
beta-adrenergic agonist with very low affinity for alpha-adrenergic receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VAPO-ISO offers entry or mid-career opportunity into a pre-launch product with ground-floor positioning for market build-out. This is ideal for professionals seeking visibility and influence in product strategy from inception through commercial launch.
Brand ManagerProduct Manager
Worked on VAPO-ISO at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.